Arovella Therapeutics (ASX:ALA) used the stage of the ASX SMIDCaps Conference to underline its ambitions in next-generation cell therapies, positioning its invariant Natural Killer T (iNKT) platform as a potential solution to some of the most pressing challenges facing oncology treatment.
Arovella showcases iNKT cell therapy platform at ASX SMIDCaps Conference
September 24, 2025 Australian Biotech
Latest Video
New Stories
-
Prescription medicines at the centre of Trump’s 'Great Healthcare Plan'
January 18, 2026 - - Latest News -
Boehringer Ingelheim again recognised as a top employer across Australia and New Zealand
January 18, 2026 - - Latest News -
The quiet and steady privatisation of this critical public health program
January 18, 2026 - - Latest News -
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News

